Cellceutix Corp (CTIX) 2.6400 $CTIX Enterococcus Faecium

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 2.6400 $CTIX

Enterococcus Faecium Infections Pipeline Review 2015 - 25 Companies & 40 Drug Profiles
M2 - Fri Jul 10, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6pz9lr/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alchemia Limited - Alvogen, Inc. - Aphios Corporation - Cellceutix Corporation - ConjuGon, Inc. - ContraFect Corporation - Enanta Pharmaceuticals, Inc. - Helix BioMedix, Inc. - LegoChem Biosciences, Inc - Lytix Biopharma AS - Melinta Therapeutics, Inc - MGB Biopharma Limited - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Nabriva Therapeutics AG - NovaBay Pharmaceuticals, Inc. - Novan, Inc. - NovoBiotic Pharmaceuticals, LLC - Omnia Molecular Ltd. - Oragenics, Inc. - Sealife PHARMA GMBH - Sentinella Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - TAXIS Pharmaceuticals, Inc. - Wockhardt Limited Drug Profiles - auriclosene - brilacidin tetrahydrochloride - CF-304 - chrysophaentin - closthioamide - EDP-788 - Epimerox - GP-505 - HB-1345 - HT-01 - HT-02 - IBN-1 - LCB-010371 - LCB-010699 - lefamulin - LTX-109 - Marinus - MBX-1162 - MGBBP-3 - MRX-I - MU-1140 - NAI-107 - NAI-603 - NVN-1000 - NVN-4428 - RX-05 - RXP-873 - SLP-0904 - SLP-0905 - SM-295291 - SM-369926 For more information visit http://www.researchandmarkets.com/research/6p...terococcus
ENTA: 45.53 (+1.12), OGEN: 1.62 (+0.04)

Klebsiella Pneumoniae Infections Pipeline Review 2015 - 18 Companies & 34 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kbn3w/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Arsanis Biosciences GmbH - Cellceutix Corporation - Debiopharm International S.A. - Melinta Therapeutics, Inc - Merck & Co., Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Pfizer Inc. - Phico Therapeutics Ltd. - Sarepta Therapeutics, Inc. - Shionogi & Co., Ltd. - Soligenix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Theraclone Sciences, Inc. - Trana Discovery, Inc. Drug Profiles - Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - BXN-112 - CB-027 - CB-618 - CC-1807 - CTIX-1278 - Debio-1454 - dusquetide - IBN-1 - Klebsiella pneumoniae vaccine - Monoclonal Antibodies for Klebsiella Pneumoniae Infections - Monoclonal Antibody for Klebsiella Pneumoniae Infections - MVX-506 - NAB-7061 - NAB-739 - NAB-741 - NOSO-95300 - NVN-1000 - NVN-4428 - PT-4 - RX-05 - RXP-792 - RXP-873 - S-649266 - Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections - SM-295291 - SM-369926 - Small Molecule for Gram-Negative Nosocomial Infections - Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - TP-076 - TP-138 - TP-600 For more information visit http://www.researchandmarkets.com/research/4kbn3w/klebsiella
TTPH: 48.76 (+2.09), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57)

Retinoblastoma - Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Wed Jun 24, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cxghfl/retinoblastoma) has announced the addition of the "Retinoblastoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - BioLineRx, Ltd. - Cellceutix Corporation - Icon Bioscience, Inc. - Neotropix, Inc. - Recombio S.L - RXi Pharmaceuticals Corporation Drug Profiles - BL-8040 - Kevetrin - melphalan - NTX-010 - nutlin-3 - racotumomab - RNAi Oligonucleotide for Retinoblastoma For more information visit http://www.researchandmarkets.com/research/cx...noblastoma

Cellceutix's Fundamental Strength Outweighs Market Cap
Jim Bowie - at Seeking Alpha - Fri Jun 19, 10:36AM CDT

MRK: 57.95 (+0.57), AMGN: 154.10 (+2.79), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)

Cellceutix Provides Update on Uplist Application
Marketwired - Mon Jun 08, 6:58AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provided shareholders an update on the status of the Company's application to uplist to the NASDAQ exchange. Cellceutix last week learned that the application remains pending due to the price of CTIX stock currently below the minimum requirement.

Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
Marketwired - Wed Jun 03, 8:27AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide shareholders insight to our presentation of certain clinical data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago that concluded on Tuesday, June 2, 2015.

Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM For Oral Mucositis Expanding to Additional Centers
Marketwired - Mon Jun 01, 7:11AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that last week a second site opened enrollment in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation. Clinical sites in Oregon and South Dakota are now enrolling patients to evaluate Brilacidin-OM for efficacy with additional sites to be added in June to keep the trial progressing in a timely manner.

Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors at American Society of Clinical Oncology (ASCO) Annual Meeting
Marketwired - Thu May 28, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today announced that the Company will be sponsoring an abstract publication at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting being held May 29 - June 2, 2015 at McCormick Place in Chicago, Illinois. The poster will provide an overview of the Company's ongoing Phase 1 clinical trial of Kevetrin as a monotherapy for advanced solid tumors being conducted at Harvard Cancer Centers' Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center and will include information on the activation of p53 through inducing p21 gene expression. The poster will be presented during the poster session titled, "Developmental Therapeutics -- Clinical Pharmacology and Experimental Therapeutics" in S Hall A.

Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
Marketwired - Tue May 26, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antibiotic applications, is pleased to announce that enrollment has commenced in the Company's Phase 2 clinical trial of Brilacidin-OM for the prevention and treatment of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.

Cellceutix to begin Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors in additional patients following IRB approval
M2 - Mon May 25, 5:49AM CDT
Biopharmaceutical company Cellceutix (OTC:CTIX) revealed on Friday that the Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has been approved for additional patient enrollment.

IRB Approves Additional Enrollment in Cellceutix's Clinical Trial of New Cancer Drug Candidate for Solid Tumors
Marketwired - Fri May 22, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the Institutional Review Board ("IRB" overseeing the Company's Phase 1 clinical trial of Kevetrin for the treatment of advanced solid tumors being conducted at Harvard University's Dana-Farber Cancer Institute and partner Beth Israel Deaconess Medical Center has approved the amended protocol to allow additional patient enrollment to the study.

Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin This Month
Marketwired - Wed May 13, 6:01AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, today announced its financial results for the three months ended March 31, 2015. A detailed report of the third quarter fiscal 2015 has been filed in a Form 10-Q with the Securities and Exchange Commission.

Cellceutix Selects Independent Directors and Committee Members
Marketwired - Mon Apr 27, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce the selection of Dr. Barry Alan Schechter, Dr. Zorik Spektor and Mark Tobin as qualified independent directors and committee members of the Company's Board of Directors.

CellCeutix: Comparing Brilacidin With SoC Daptomycin
Kanak Kanti De - at Seeking Alpha - Tue Apr 21, 12:37PM CDT


Cellceutix Provides Corporate Update
Marketwired - Tue Apr 21, 9:06AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to provide shareholders with a comprehensive update on current corporate activity and pipeline development.

Cellceutix PIND Meeting Scheduled With FDA for Hidradenitis Suppurativa
Marketwired - Mon Apr 13, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted the Company's request for a Pre-Investigational New Drug (PIND) meeting to discuss the Company's plans for a Phase 2 clinical trial with one of the Company's Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa. The meeting is scheduled during the third week of May.

Cellceutix Corporation - Product Pipeline Review - 2015
M2 - Thu Apr 09, 1:48AM CDT
Summary

Cellceutix closes $30M stock purchase agreement
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 7:59AM CDT


Cellceutix Enters Into a $30 Million Common Stock Purchase Agreement
Marketwired - Wed Apr 01, 6:00AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that Cellceutix has signed a $30 million stock purchase agreement with Aspire Capital Fund, LLC. Pursuant to the Agreement, Aspire has committed to purchase over the next 3 years up to $30 million of Cellceutix's common stock based on the prevailing market prices at the time of each sale. The timing of the purchases will be at the sole discretion of Cellceutix. Aspire Capital has previously provided the Company with $30 million in equity capital in two similar transactions. Additional details of the Agreement with Aspire Capital have been filed in a Report on Form 8-K with the U.S. Securities and Exchange Commission.

Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin, No Adverse Events Reported
Marketwired - Tue Mar 24, 7:29AM CDT
Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to announce that the tenth cohort in the Company's Phase 1 clinical trial of Kevetrin for advanced solid tumors being conducted at Harvard's Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has been completed. Patients in the tenth cohort were treated with 450 mg/m2 of Kevetrin with no adverse events reported.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 81

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 143

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 189

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 277

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 159

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading

Top 5 Most Recently Viewed Articles

S&P CoreLogic Case-Shiller Index Highlights Growth Trends

Updated Category News Views 141

Overview of the Recent S&P CoreLogic Case-Shiller Index S&P Dow Jones Indices has released the results from its well-regarded S&P CoreLogic Case-Shiller Indices, revealing insightful trends in the U.S. housing market. The data indicates a notable 3.9% annual gain for December, reflecting a slight increase from previous figures earlier in the year. With over 27 years of...

Continue Reading
Baader Bank Enhances OTC Trading with New Extended Hours

Updated Category News Views 95

Baader Bank Expands OTC Trading Hours MUNICH - Baader Bank AG, a prominent player in the German financial services sector, has recently announced a significant enhancement to its over-the-counter (OTC) trading hours. Starting today, clients can now engage in trading activities from 07:30 to 23:00. This extension is part of the bank's strategic initiative to bolster its...

Continue Reading
Nokia Strengthens Alliance with SoftBank Through Network Upgrade

Updated Category News Views 644

Nokia Strengthens Alliance with SoftBank Through Network Upgrade Nokia has taken significant strides in enhancing its partnership with SoftBank Corp. through a new agreement focused on the modernization of network systems in Japan. This expansion involves the deployment of innovative 4G and 5G radio access solutions underpinned by Nokia's advanced AirScale portfolio....

Continue Reading
IS4S Launches Office to Enhance Regional Defense Solutions

Updated Category News Views 251

IS4S Expands Operations with New Office Launch Integrated Solutions for Systems, Inc. (IS4S) has proudly announced the opening of its latest office, strategically situated to support its operations in New England. This new location enhances IS4S's capacity to engage with stakeholders associated with various Air Force programs, especially those managed by the Air Force...

Continue Reading
Discover the Future of Contract Management with CobbleStone

Updated Category News Views 141

CobbleStone Software to Showcase Contract Management Solutions CobbleStone Software is set to exhibit its cutting-edge, AI-enhanced contract management solutions at an upcoming event, bringing together legal professionals from various sectors. This performance is part of the anticipated 2025 ACC Annual Meeting, where the company will engage with leaders in the legal...

Continue Reading